# Chandra Leo

> Chandra Leo is a Series B investor at HBM Partners backing Biotechnology and Health Care. See 5 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [HBM Partners](https://shizune.co/investors/profile/hbm-partners)
- Total investments: 5
- Last investment: Aug 2023
- Lead investor: 20%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/chandraleo

Chandra Leo is a Series B investor at HBM Partners focused on Biotechnology and Health Care. Chandra Leo has over fifteen years of experience in private equity, clinical practice and biomedical research. He is a Former postdoctoral scientist at Stanford University, physician at University Hospital Leipzig and principal at Wellington Partners. He Completed medical studies in Berlin and London, doctoral degree from Freie Universität Berlin(Charité), MBA degree with distinction from INSEAD. He was a board member of Galecto Biotech and Gynesonics, board observer at TP Therapeutics.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 4 | 80% |
| Health Care | 3 | 60% |
| Medical | 2 | 40% |
| Life Science | 2 | 40% |
| Health Diagnostics | 2 | 40% |

7 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 2 | 40% |
| Series D | 2 | 40% |
| Series C | 1 | 20% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Israel | 1 | 20% |
| Denmark | 1 | 20% |
| Switzerland | 1 | 20% |
| United States | 1 | 20% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Fore Biotherapeutics | We are a precision oncology company pioneering the development of cancer therapies guided by our proprietary functional genomics. | $75M | Series D | Aug 23, 2023 |  |
| Dren Bio | Dren Bio is a biotechnology company with a portfolio of attractive projects focused on powerful protein engineering technologies for the depletion of cells, protein aggregates, and other disease-causing agents. It is a holding company business model aimed at creating value with multiple projects as stand-alone assets. | $65M | Series B | Jun 14, 2022 |  |
| Galecto | Galecto develops small molecules for the treatment of severe diseases, including fibrosis and cancer. The company lead product candidate, GB0139, is an inhaled inhibitor of galectin-3. GB0139 is being developed for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, in which there is high unmet medicalneed. Galecto was founded in 2011, builds on more than 10 years of research centering on the role of galectin-3 and LOXL-2, and the use of modulators of these proteins to treat fibrosis-related diseases and cancer. Combined with a strong patent estate, these assets give Galecto a unique therapeutic platform. | $64M | Series D | Sep 25, 2020 |  |
| Monte Rosa Therapeutics | Monte Rosa Therapeutics is a biotechnology company that develops cancer therapeutics that modulate protein degradation pathways. Its rational approach in targeting disease-causing proteins for degradation will deliver pioneering therapies for cancer and beyond. | $96M | Series B | Sep 24, 2020 |  |
| Galecto | Galecto develops small molecules for the treatment of severe diseases, including fibrosis and cancer. The company lead product candidate, GB0139, is an inhaled inhibitor of galectin-3. GB0139 is being developed for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, in which there is high unmet medicalneed. Galecto was founded in 2011, builds on more than 10 years of research centering on the role of galectin-3 and LOXL-2, and the use of modulators of these proteins to treat fibrosis-related diseases and cancer. Combined with a strong patent estate, these assets give Galecto a unique therapeutic platform. | $83.8M | Series C | Oct 26, 2018 |  |

5 of 5 investments shown.

## Co-investors
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund, 4 deals together
- [Cormorant Asset Management](https://shizune.co/investors/profile/cormorant-asset-management) — VC Fund, 3 deals together
- [SR One](https://shizune.co/investors/profile/sr-one) — VC Fund, 3 deals together
- [Aisling Capital](https://shizune.co/investors/profile/aisling-capital) — VC Fund, 2 deals together
- [Bristol-Myers Squibb](https://shizune.co/investors/profile/bristol-myers-squibb) — VC Fund, 2 deals together
- [Google Ventures](https://shizune.co/investors/profile/google-ventures) — VC Fund, 2 deals together

## About HBM Partners

VC Fund · Zug, Switzerland

HBM Partners focuses on venture, growth and buy-out financings of private companies as well as investments in public companies.The HBM funds invest in entrepreneurial biopharma and other healthcare-related companies in Europe, North America, India and other Emerging Markets. Their team supports the growth of the portfolio companies through allstages of development, focusing on adding value by leveraging its experience and HBM's world-wide network in the industry. Investments usually range between $5 million to $50 million.

5 contacts available at HBM Partners.

| Name | Title | Profile |
| --- | --- | --- |
| Andreas Wicki | Founder & CEO | https://shizune.co/investors/profile/andreas-wicki |
| Chandra Leo | Partner | https://shizune.co/investors/profile/chandra-leo |
| Erwin Troxler | CFO | https://shizune.co/investors/profile/erwin-troxler |
| Axel Bolte | Venture Partner | https://shizune.co/investors/profile/axel-bolt |
| Saeid Akhtari | Managing Director | https://shizune.co/investors/profile/saeid-akhtari |

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Chandra Leo invest in?

Chandra Leo invests primarily in Biotechnology, Health Care and Medical startups, most often at Series B and Series D stage. Most of the 5 investments tracked by Shizune back companies in Israel. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Chandra Leo last invest?

The most recent investment recorded for Chandra Leo closed in Aug 2023. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co